Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Repurchasing up to $30M of Shares

NEW YORK (GenomeWeb) – Qiagen has launched the third tranche of a share repurchase program for up to approximately $30 million. 

In a document filed with the US Securities and Exchange Commission, the firm said that a maximum of 2 million shares will be repurchased at a maximum per-share price no greater than 10 percent above the average closing price of the last five trading days prior to the day of purchase on the Frankfurt Stock Exchange. 

The third tranche of the repurchase program lasts until Aug. 31, Qiagen said. In the two previous tranches carried out last year, the firm repurchased more than 2.1 million shares for about $50 million. 

Qiagen said that the repurchased shares will be held in treasury to satisfy obligations from exchangeable debt instruments and/or employee share-based remuneration plans.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.